NextCure (NXTC) Competitors $0.70 -0.06 (-7.53%) Closing price 02/12/2025 04:00 PM EasternExtended Trading$0.72 +0.03 (+3.98%) As of 02/12/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NXTC vs. AVTX, CLSD, IGMS, GALT, RANI, ALTS, PYXS, KPTI, ASRT, and INCRShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Avalo Therapeutics (AVTX), Clearside Biomedical (CLSD), IGM Biosciences (IGMS), Galectin Therapeutics (GALT), Rani Therapeutics (RANI), Janone (ALTS), Pyxis Oncology (PYXS), Karyopharm Therapeutics (KPTI), Assertio (ASRT), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry. NextCure vs. Avalo Therapeutics Clearside Biomedical IGM Biosciences Galectin Therapeutics Rani Therapeutics Janone Pyxis Oncology Karyopharm Therapeutics Assertio InterCure NextCure (NASDAQ:NXTC) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking. Do analysts rate NXTC or AVTX? NextCure presently has a consensus price target of $4.00, suggesting a potential upside of 474.47%. Avalo Therapeutics has a consensus price target of $40.00, suggesting a potential upside of 420.83%. Given NextCure's stronger consensus rating and higher possible upside, equities research analysts plainly believe NextCure is more favorable than Avalo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Avalo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the MarketBeat Community favor NXTC or AVTX? NextCure received 74 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 64.52% of users gave NextCure an outperform vote while only 33.33% of users gave Avalo Therapeutics an outperform vote. CompanyUnderperformOutperformNextCureOutperform Votes8064.52% Underperform Votes4435.48% Avalo TherapeuticsOutperform Votes633.33% Underperform Votes1266.67% Do institutionals & insiders believe in NXTC or AVTX? 42.7% of NextCure shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 13.3% of NextCure shares are held by insiders. Comparatively, 0.3% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, NXTC or AVTX? NextCure has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Does the media favor NXTC or AVTX? In the previous week, NextCure had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 2 mentions for NextCure and 0 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.87 beat NextCure's score of 0.94 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment NextCure Positive Avalo Therapeutics Very Positive Is NXTC or AVTX more profitable? NextCure's return on equity of -62.50% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NextCureN/A -62.50% -53.67% Avalo Therapeutics N/A -442.16%122.99% Which has stronger valuation and earnings, NXTC or AVTX? Avalo Therapeutics has higher revenue and earnings than NextCure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNextCureN/AN/A-$62.72M-$2.09-0.33Avalo Therapeutics$1.92M41.56-$31.54MN/AN/A SummaryNextCure beats Avalo Therapeutics on 7 of the 13 factors compared between the two stocks. Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.12M$6.86B$5.65B$9.04BDividend YieldN/A2.90%5.31%4.00%P/E RatioN/A8.9988.1218.99Price / SalesN/A311.371,013.0178.41Price / CashN/A75.4646.0938.87Price / Book0.175.535.135.00Net Income-$62.72M$123.50M$113.24M$222.75M7 Day Performance-11.86%-3.29%-1.39%-1.01%1 Month Performance-10.50%-0.08%4.85%4.04%1 Year Performance-47.25%5.40%25.24%21.71% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.5101 of 5 stars$0.70-7.5%$4.00+474.5%-49.5%$22.12MN/A0.0090Short Interest ↑News CoverageGap UpHigh Trading VolumeAVTXAvalo Therapeutics3.6935 of 5 stars$7.96-2.7%$40.00+402.5%+58.7%$82.70M$1.92M0.0040Positive NewsCLSDClearside Biomedical2.0609 of 5 stars$1.09-3.5%$5.33+389.3%-25.4%$82.67M$8.23M-2.4230High Trading VolumeIGMSIGM Biosciences4.8242 of 5 stars$1.38-2.8%$5.50+298.6%-92.0%$82.06M$2.13M-0.38190GALTGalectin Therapeutics1.2672 of 5 stars$1.30-0.8%$11.00+746.2%-21.1%$81.59MN/A-1.789RANIRani Therapeutics3.58 of 5 stars$1.42-6.6%$12.33+768.5%-52.7%$81.35MN/A-1.34110Gap UpALTSJanoneN/A$5.74-1.2%N/AN/A$80.76M$39.61M0.00170Positive NewsPYXSPyxis Oncology2.9572 of 5 stars$1.33-5.0%$9.20+591.7%-73.0%$79.10MN/A-1.2960Positive NewsKPTIKaryopharm Therapeutics3.846 of 5 stars$0.62-1.3%$5.00+702.7%-54.9%$78.60M$148.44M-0.55380Analyst ForecastNews CoverageASRTAssertio3.4105 of 5 stars$0.82+2.3%$3.25+296.3%-0.2%$78.29M$152.07M-1.1220Short Interest ↓News CoveragePositive NewsINCRInterCure1.184 of 5 stars$1.72+0.3%N/A-7.8%$78.15M$96.61M0.00350News CoveragePositive NewsGap Down Related Companies and Tools Related Companies AVTX Competitors CLSD Competitors IGMS Competitors GALT Competitors RANI Competitors ALTS Competitors PYXS Competitors KPTI Competitors ASRT Competitors INCR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NXTC) was last updated on 2/13/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.